Quinidine - Revision history

SLuckettG: /* Administration */

2019-03-07T19:23:35Z

Administration

← Older revision		Revision as of 19:23, 7 March 2019
Line 1:		Line 1:
	==Administration==		==Administration==
	*Type: [[Antimalarial]], [[Antiarrhythmic]]		*Type: [[Antimalarial]], [[Antiarrhythmic]] (Class I)
	*Dosage Forms:		*Routes of Administration: IV (discontinued in America), oral
	*Routes of Administration: IV, oral		*Common Trade Names:
	*Common Trade Names:		**Quinaglute
			**Quinidex

	==Adult Dosing==		==Adult Dosing==

Mholtz: Text replacement - "OR" to "'''OR'''"

2017-05-31T01:24:49Z

Text replacement - "OR" to "'''OR'''"

← Older revision		Revision as of 01:24, 31 May 2017
Line 11:		Line 11:

	===Severe [[malaria]]===		===Severe [[malaria]]===
	*Load 10 mg/kg IV over 2hrs, then 0.02 mg/kg/min IV/PO x3 days, in conjunction with [[doxycycline]] OR		*Load 10 mg/kg IV over 2hrs, then 0.02 mg/kg/min IV/PO x3 days, in conjunction with [[doxycycline]] '''OR'''
	*Load 24 mg/kg IV infused over 4 hours, then 12 mg/kg IV infused over 4h q8h starting 8h after initial loading dose		*Load 24 mg/kg IV infused over 4 hours, then 12 mg/kg IV infused over 4h q8h starting 8h after initial loading dose

Line 62:		Line 62:
	**Sinus rhythym restored		**Sinus rhythym restored
	**QRS complex widens > 130% of pre-treatment QRS duration		**QRS complex widens > 130% of pre-treatment QRS duration
	**QTc widens > 130% of pre-treatment duration OR > 500 ms		**QTc widens > 130% of pre-treatment duration '''OR''' > 500 ms
	**Disappearance of T-waves		**Disappearance of T-waves
	**Development of significant tachycardia, symptomatic bradycardia, hypotension		**Development of significant tachycardia, symptomatic bradycardia, hypotension

ClaireLewis at 01:36, 13 November 2016

2016-11-13T01:36:22Z

← Older revision		Revision as of 01:36, 13 November 2016
Line 1:		Line 1:
	==Administration==		==Administration==
	*Type:		*Type: [[Antimalarial]], [[Antiarrhythmic]]
	*Dosage Forms:		*Dosage Forms:
	*Routes of Administration:		*Routes of Administration: IV, oral
	*Common Trade Names:		*Common Trade Names:

Line 11:		Line 11:

	===Severe [[malaria]]===		===Severe [[malaria]]===
	*Load 10 mg/kg IV over 2hrs, then 0.02 mg/kg/min IV/PO x3 days, in conjunction with [[doxycycline]]		*Load 10 mg/kg IV over 2hrs, then 0.02 mg/kg/min IV/PO x3 days, in conjunction with [[doxycycline]] OR
			*Load 24 mg/kg IV infused over 4 hours, then 12 mg/kg IV infused over 4h q8h starting 8h after initial loading dose

	==Pediatric Dosing==		==Pediatric Dosing==
			*Malaria: same weight-based dosing as above

	==Special Populations==		==Special Populations==
	*[[Drug Ratings in Pregnancy\|Pregnancy Rating]]:		*[[Drug Ratings in Pregnancy\|Pregnancy Rating]]: C
	*[[Lactation risk categories\|Lactation risk]]:		*[[Lactation risk categories\|Lactation risk]]: Infant risk minimal
	~~===~~Renal ~~Dosing===~~		*Renal dosing: No adjustment
	*Adult:		*Hepatic dosing: May lengthen half-life
	*~~Pediatric:~~
	~~===~~Hepatic ~~Dosing===~~
	*Adult:
	*Pediatric:

	==Indications==		==Indications==
Line 34:		Line 32:
	==Contraindications==		==Contraindications==
	*Allergy to class/drug		*Allergy to class/drug
			*Cardiac rhythm dependent upon junctional or idioventricular pacemaker (in absence of artificial pacemaker)
			*Myasthenia gravis
			*History of ITP or TTP associated with quinine or quinidine

	==Adverse Reactions==		==Adverse Reactions==
	===Serious===		===Serious===
			*Prolonged QT, torsades de points, ventricular arrythmia
			*Hepatotoxicity
			*Kidney disease
	===Common===		===Common===
			*Diarrhea, nausea/vomiting
			*Headache, lightheadedness
			*Palpitations
			*Rash

	==Pharmacology==		==Pharmacology==
	*Half-life:		*Half-life: 3-8h
	*Metabolism:		*Metabolism: Hepatic
	*Excretion:		*Excretion:

	==Mechanism of Action==		==Mechanism of Action==
			*Class IA antiarrhythmic: inhibits depolarizing sodium channels in cardiac muscle and purkinje fibers
			*Antimalarial action: intraerythrocytic schizonticide to p. vivax and p. malariae, acts against asexual erythrocytic phase of p. falciparum

	==Comments==		==Comments==
Line 58:		Line 67:

	==See Also==		==See Also==
			*[[Antimalarial medications]]
			*[[Antiarrhythmics]]

	==References==		==References==
Line 63:		Line 74:
	[[Category:Pharmacology]]		[[Category:Pharmacology]]
	[[Category:Cardiology]]		[[Category:Cardiology]]
			[[Category:ID]]

Rossdonaldson1 at 14:47, 2 October 2016

2016-10-02T14:47:44Z

@@ Line 1: / Line 1: @@
-==Background==
+==Administration==
-*Inexpensive with restricted indications, causing it to be inaccessible in many areas globally
+*Type:
-*Main manufacturer halted production in 2010<ref>Olsson  G.; To the editor—Market withdrawal of quinidine bisulfate (Kinidin Durules) in 2006. Heart Rhythm. 2010;7:864</ref>
+*Dosage Forms:
-*Historically both supraventricular tachydysrhytmia, ventricular dysrhythmia, malaria treatment, many other first-line therapies have replaced its use
+*Routes of Administration:
 *An effective treatment and prevention strategy for<ref>Viskin S et al. Quinidine, A Life-Saving Medication for Brugada Syndrome, Is Inaccessible in Many Countries. J Am Coll Cardiol. 2013;61(23):2383-2387.</ref>:
 **[[Brugada syndrome]] arrhythmic [[electrical storm]]
@@ Line 8: / Line 31: @@
 **Early repolarization syndrome (though NOT benign, see [[benign early repolarization]])
 **Congenital [[short QT syndrome]]
-==Administration<ref>Athena Health. Epocrates. Quinidine Gluconate Monograph. https://online.epocrates.com/u/10a72/quinidine+gluconate.</ref>==
-*For ventricular dysrhythmias:
+==Contraindications==
-**Quinidine gluconate IV 0.25 mg/kg/min over 20-40 min, max 10 mg/kg per conversion attempt
+*Allergy to class/drug
-**PO alternative: 648 mg PO q8 x3-4 doses
-*For severe [[malaria]]: load 10 mg/kg IV over 2hrs, then 0.02 mg/kg/min IV/PO x3 days, in conjunction with [[doxycycline]]
+==Adverse Reactions==
-==Monitoring==
+===Serious===
 *Discontinue quinidine infusion if<ref>Quinidine gluconate dilution. GlobalRPH. http://www.globalrph.com/quinidine_gluconate_dilution.htm</ref>:
 **Sinus rhythym restored
@@ Line 21: / Line 57: @@
 **Development of significant tachycardia, symptomatic bradycardia, hypotension
-==Sources==
+==See Also==
 <references/>
+[[Category:Pharmacology]]
 [[Category:Cardiology]]

ClaireLewis: /* Monitoring */

2016-09-29T02:59:11Z

Monitoring

← Older revision		Revision as of 02:59, 29 September 2016
Line 16:		Line 16:
	*Discontinue quinidine infusion if<ref>Quinidine gluconate dilution. GlobalRPH. http://www.globalrph.com/quinidine_gluconate_dilution.htm</ref>:		*Discontinue quinidine infusion if<ref>Quinidine gluconate dilution. GlobalRPH. http://www.globalrph.com/quinidine_gluconate_dilution.htm</ref>:
	**Sinus rhythym restored		**Sinus rhythym restored
	**QRS complex widens > 130% of pre-Tx QRS duration		**QRS complex widens > 130% of pre-treatment QRS duration
	**QTc widens > 130% of pre-Tx duration OR > 500 ms		**QTc widens > 130% of pre-treatment duration OR > 500 ms
	**Disappearance of T-waves		**Disappearance of T-waves
	**Development of significant tachycardia, symptomatic bradycardia, hypotension		**Development of significant tachycardia, symptomatic bradycardia, hypotension

Kxl328 at 20:50, 5 August 2016

2016-08-05T20:50:06Z

@@ Line 8: / Line 8: @@
 **Early repolarization syndrome (though NOT benign, see [[benign early repolarization]])
 **Congenital [[short QT syndrome]]
 ==Sources==

Kxl328 at 20:37, 5 August 2016

2016-08-05T20:37:18Z

← Older revision		Revision as of 20:37, 5 August 2016
Line 10:		Line 10:

	==Sources==		==Sources==
	</~~references~~>		<references/>

	[[Category:Cardiology]]		[[Category:Cardiology]]

Kxl328: Created page with "==Background== Inexpensive with restricted indications, causing it to be inaccessible in many areas globally Main manufacturer halted production in 2010Olsson G.; To t..."

2016-08-05T20:36:49Z

Created page with "==Background== *Inexpensive with restricted indications, causing it to be inaccessible in many areas globally *Main manufacturer halted production in 2010<ref>Olsson G.; To t..."

New page

==Background==
*Inexpensive with restricted indications, causing it to be inaccessible in many areas globally
*Main manufacturer halted production in 2010<ref>Olsson G.; To the editor—Market withdrawal of quinidine bisulfate (Kinidin Durules) in 2006. Heart Rhythm. 2010;7:864</ref>
*Historically both supraventricular tachydysrhytmia, ventricular dysrhythmia, malaria treatment, many other first-line therapies have replaced its use
*An effective treatment and prevention strategy for<ref>Viskin S et al. Quinidine, A Life-Saving Medication for Brugada Syndrome, Is Inaccessible in Many Countries. J Am Coll Cardiol. 2013;61(23):2383-2387.</ref>:
**[[Brugada syndrome]] arrhythmic [[electrical storm]]
**Idiopathic ventricular fibrillation
**Early repolarization syndrome (though NOT benign, see [[benign early repolarization]])
**Congenital [[short QT syndrome]]

==Sources==
</references>

[[Category:Cardiology]]